The Patient with Newly Diagnosed Ulcerative Colitis


Patients can be relatively ill informed regarding the nature of their UC, its management, and its ultimate prognosis.
Generally, disease extent is divided into three categories: ulcerative proctitis, left-sided disease, and pancolitis.
A simple approach with frequently asked questions (FAQs) is a highly desirable and efficient means of transmitting information.
Clinical experience reinforces that most patients have similar questions upon diagnosis with UC.
Anticipating these questions and tailoring them to a particular patient's disease severity and extent should streamline follow-up and also mitigate confusion.


  1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559–68.
  2. Satsangi J, Siverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
  3. Yamamoto T, Nakahigashi M, Saniabadi AR. Diet and inflammatory bowel disease – epidemiology and treatment. Aliment Pharmacol Ther 2009;30:99–112.
  4. Rosenberg LN, Peppercorn MA. Efficacy and safety for drugs for ulcerative colitis. Expert Opin Drug Saf 2010;9:573–92.
  5. Ǿrding Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease and after surgery compared with a population sample. Gastroenterology 2002;122:15–9.
  6. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–23.
  7. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738–45.